Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARS-CT
2025-521350-41-01Phase 3Authorised
- Sponsor
- Foundation for the Study of Nanoneurosciences and Neuroregeneration
- Start
- Jul 2025
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Cerebrolysin with Placebo (2 arms). Primary endpoint: Action Research Arm Test (ARAT). Planned start Jul 2025; status: authorised.
02
Drugs
cerebrolysin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-521350-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521350-41-01.